Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Bcl-2 Stories

2014-01-08 17:07:21

Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells. The discovery offers hope for treating many types of cancer that are driven to grow and spread through the actions of a cancer-causing protein called MYC. Up to 70 per cent of human cancers, including many leukemias and lymphomas, have unusually high levels of MYC, which causes cancerous changes in cells by...

2013-08-29 12:26:37

After identifying a protein that blocks death of high-risk acute lymphoblastic leukemia (ALL) cells, scientists use two-drug combination therapy to offer hope to children and adults with the disease MEMPHIS, Tenn., Aug. 29, 2013 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective method of killing...

2013-07-09 11:33:27

Knocking down cancer cell survival signals increases the effectiveness of chemotherapy Pancreatic cancer is one of the most deadly and intractable forms of cancer, with a 5-year survival rate of only 6%. Novel therapies are urgently needed, as conventional and targeted approaches have not been successful and drug resistance is an increasing problem. Previously it had been thought that poor penetration of the drugs into pancreas tumors was the main reason for treatment failure. But now a...

New Compound BH3 Mimetics Future Of Breast Cancer Treatment
2013-07-09 09:40:18

[ Watch the Video: New Anti-Cancer Compound Shows Promise For Breast Cancer ] Rebekah Eliason for redOrbit.com - Your Universe Online Scientists from Melbourne, Australia recently discovered compounds currently being researched to treat leukemia may also be effective in treating the most common form of breast cancer. Researchers found a group of anti-cancer compounds known as BH3-mimetics are effective for treating estrogen receptor-positive (ER-positive) forms of breast cancers when...

2013-05-15 20:23:38

Enrollment in Phase 1 Clinical Trials of ABT-199 in Chronic Lymphocytic Leukemia Continues NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago. Data being presented include the results from two clinical trials evaluating the safety and...

2013-04-17 17:24:41

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent. In the study, published in the journal Cancer Research, researchers...

2013-01-23 12:06:07

Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues. The finding suggests that these so-called autoimmune diseases could be treated with existing medications that force long-lived immune system cells to die. In the development of the immune system, some cells are produced that have...

2012-11-09 08:27:21

PLYMOUTH, Mich., Nov. 9, 2012 /PRNewswire-USNewswire/ -- ProNAi Therapeutics, Inc., a private DNAi cancer drug development company, recently concluded its initial human clinical trial of PNT2258, a first-in-class, nucleic acid drug. It is presenting the results of the Phase I study of PNT2258, an anti-Bcl-2 cancer drug, at the annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, a conference hosted by the European Organization for Research and Treatment of Cancer,...

2012-09-20 02:28:45

CAMBRIDGE, Mass., Sept. 20, 2012 /PRNewswire/ -- Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has entered into a strategic partnership with The Leukemia & Lymphoma Society® (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies. Under the terms of the agreement, LLS will provide up to $7.5 million in funding to support...

2012-05-30 08:35:20

Scientists build a synthetic peptide that overcomes cancer cells´ survival defenses Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment. The strategy could pave the way for much needed new therapies to treat relapsed and refractory blood cancers, which are difficult to...